Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

14.22
-0.0150-0.11%
Post-market: 14.260.0450+0.32%19:53 EDT
Volume:11.92M
Turnover:169.86M
Market Cap:6.44B
PE:-20.14
High:14.75
Open:14.45
Low:13.95
Close:14.23
52wk High:15.30
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:0.40
T/O Rate:3.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:8.75
PE(LYR):-12.99

Loading ...

Movement Alert|Iovance Biotherapeutics, Inc. Rises 10.03% in Regular Trading, Q2 Earnings Beat Fuels Continued Upward Momentum

Market Focus
·
Aug 20

Iovance Biotherapeutics (IOVA) Earnings Put Its Valuation Back In Focus

Simply Wall St.
·
Aug 19

Iovance Biotherapeutics put volume heavy and directionally bearish

TIPRANKS
·
Aug 17

Iovance Biotherapeutics (IOVA) Stock Price Trails Record Revenue And Margin Gains

Simply Wall St.
·
Aug 08

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock is Tumbling.

Dow Jones
·
Aug 08

Iovance Biotherapeutics is Maintained at Market Outperform by Citizens

Dow Jones
·
Aug 07

Iovance Biotherapeutics price target raised to $8 from $5 at Citizens

TIPRANKS
·
Aug 07

Iovance Biotherapeutics price target raised to $13 from $11 at Barclays

TIPRANKS
·
Aug 07

Barclays Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)

TIPRANKS
·
Aug 07

US FDA Approves Replimune's Skin Cancer Drug

Reuters
·
Aug 07

Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results

Benzinga Earnings
·
Aug 07

U.S. Stocks on the MOVE-Ralph Lauren, Sempra, Parker-Hannifin, Lincoln International

Reuters
·
Aug 07

Analysts’ Opinions Are Mixed on These Healthcare Stocks: VistaGen Therapeutics (VTGN), Iovance Biotherapeutics (IOVA) and Aurinia Pharmaceuticals (AUPH)

TIPRANKS
·
Aug 06

Iovance Biotherapeutics up over 37%, on Pace for Largest Percent Increase Since June 2016

Dow Jones
·
Aug 06

Iovance Biotherapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Iovance Publishes Corporate Presentation Highlighting Amtagvi TIL Therapy Rollout and Pipeline Expansion in Solid Tumors

Reuters
·
Aug 06

Iovance Gains After Q2 Revenue Beat

Reuters
·
Aug 06

Iovance Q2 2026 Earnings: Amtagvi Drives 66% Revenue Growth and a Narrower Loss

TradingKey
·
Aug 06

Earnings Flash (IOVA) Iovance Biotherapeutics Posts Q2 Loss $0.11 a Share, vs. FactSet Est of $0.13 Loss

MT Newswires Live
·
Aug 06

Iovance Biotherapeutics Shares Rise 13.4% Premarket After Q2 Revenue Beat

THOMSON REUTERS
·
Aug 06